Canada: Health Canada Approval and Provincial Coverage Differences
Health Canada approves GLP-1 drugs nationally, but public drug coverage is administered provincially, creating access differences similar to the EU's member-state model.
By the GLP Semaglutide editorial team · Last updated June 18, 2026
Health Canada evaluates and approves drugs for the national market, but public drug insurance programs are administered separately by each province and territory, meaning covered access to a given GLP-1 drug can differ by where a patient lives.
Private insurance fills gaps
Many Canadians access prescription drug coverage through employer-sponsored private insurance rather than public plans, and private plan coverage of GLP-1 drugs for weight management varies by insurer and employer, similar to the U.S. employer-plan pattern.
Cross-border purchasing questions
Canada has occasionally been discussed as a lower-cost source for U.S. patients; drug importation between the two countries is subject to both nations' regulatory rules, and personal cross-border prescription purchasing carries legal and supply-chain caveats worth checking directly with each country's regulator.
Primary sources